Nanomedicine (London, England)最新文献

With the rapid development of nanotechnology, nanoultrasonography has emerged as a promising medical imaging technique that demonstrates significant potential in the diagnosis and treatment of gastrointestinal (GI) diseases. This review discusses the applications of nanoultrasonography in the gastrointestinal field, including improvements in imaging resolution, diagnostic accuracy, latest research findings, and prospects for clinical application. By analyzing existing literature, we explore the role of nanoultrasonography in enhancing imaging resolution, enabling targeted drug delivery, and improving therapeutic outcomes, thereby providing a reference for future research directions.

Phytochemicals are typically natural bioactive compounds or metabolites produced by plants. Phytochemical-loaded nanocarrier systems, designed to overcome bioavailability limitations and enhance therapeutic effects, have garnered significant attention in recent years. The coronavirus disease 2019 (COVID-19) pandemic has intensified interest in the therapeutic application of phytochemicals to combat viral infections. This review explores nanoparticle-based treatment strategies incorporating phytochemicals for antiviral application, highlighting their demonstrated antiviral mechanisms. It specifically examines the antiviral activities of phytochemical-loaded nanosystems against (i) influenza virus (IAV), respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); (ii) mosquito-borne viruses [dengue (DENV), Zika (ZIKV), and Chikungunya (CHIKV)]; and (iii) sexually transmitted/blood borne viruses [e.g. herpes simplex virus (HSV), human papillomavirus (HPV), and human immunodeficiency virus (HIV)]. Furthermore, this review highlights the emerging role of these nanosystems in photodynamic therapy (PDT)-mediated attenuation of viral proliferation, and offers a perspective on the future directions of research in this promising area of multimodal therapeutic approach.

Introduction: Colorectal cancer (CRC) remains a serious threat to humans worldwide. In this study, we used bibliometric analysis of the scientific literature to assess the trends and prospects of nanotechnology applications in CRC.

Materials and methods: We used the Web of Science Core Collection database to screen relevant publications on nanotechnology and CRC from 2004 to 2023 based on the inclusion criteria. Bibliometric analyses were performed on all selected publication and citation data. Visual analysis using VOSviewer and CiteSpace intuitively reflected the hotspots in this field.

Results: In total, 2040 publications on nanotechnology in CRC were identified for this two-decade analysis. China (443, 29.14%) and the USA (199, 13.09%) were the top two most productive countries, and Sichuan University was the most prolific institution. The most influential journal was the International Journal of Nanomedicine. The author with the most papers was Li L. "Nanoparticles," "drug delivery," and "CRC" were the most common keywords. Green synthesis and gold nanoparticles were peripheral, incompletely developed topics.

Conclusion: This study provides a comprehensive overview of nanomaterials in CRC as clinical medicine, enriching the body of evidence in this field.

Background: Drug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting agent, such as the humanized anti-GPC3 antibody GC33 (condrituzumab), could be attached to their surface. Here, we investigated the use of idarubicin-loaded CS-NBs for HCC treatment and a GC33-derived minibody (that we named 4A1) to enhance CS-NB delivery.

Methods: Various CS-NB formulations were prepared with or without 4A1 conjugation and idarubicin loading.

Results: CS-NBs had a positive charge and a diameter of about 360 nm. In in-vitro experiments using the HCC-like HUH7 cell line, CS-NBs showed a cytotoxic effect once loaded with idarubicin. In-vivo biodistribution in HUH7 tumor-bearing xenograft mice demonstrated that CS-NBs can accumulate in the tumor mass. This effect was enhanced by 4A1 conjugation (p = 0.0317). In HUH7 tumor-bearing xenograft mice, CS-NBs loaded with idarubicin and conjugated or not conjugated with 4A1 were both able to slow tumor growth, to increase mouse survival time compared to free idarubicin (p = 0.00044 and 0.0018, respectively) as well as to reduce drug side effects.

Conclusions: CS-NBs loaded with idarubicin can be a useful drug delivery strategy for HCC treatment.

Recent advancements in tumor therapy have underscored the potential of biomaterials-mediated biomineralization for tumor blockade. By precisely regulating biomineralization and constructing nanomineralized structures at the cellular level, this therapy achieves multi-dimensional targeted inhibition of tumors. Mineralized precursor molecules are engineered to selectively recognize and bind to proteins on the tumor cell membrane, obstructing signal transduction. Biomineralized materials directly target the tumor cell membrane, disrupting its biological functions and inducing cell apoptosis. Additionally, these materials infiltrate the mitochondria of tumor cells, disrupting energy metabolism through mineralization and significantly impairing tumor viability. This biomaterials-mediated approach enhances treatment precision and efficacy while mitigating side effects, offering a unique approach to tumor therapy.

Background: Recently, we developed AT101, an IgM-class mouse monoclonal antibody directed against glypican-1 (GPC1), a proteoglycan that can be considered as useful target for glioblastoma multiforme (GBM) treatment being specifically and highly expressed on GBM cell surface. Here, we proposed the use of AT101 as targeting agent in a drug delivery nanoplatfom to effectively deliver chitosan nanobubbles (NBs) for GBM treatment.

Methods: Chitosan NBs were prepared and conjugated with AT101 or left unconjugated as control.

Results: The ability of AT101 to bind the GPC1 protein was demonstrated by flow cytometry and immunofluorescence analysis in the "GBM-like" GPC1-expressing cell lines U-87 MG and T98G. AT101 was shown to bind GPC1-expressing GBM tumor samples by immunofluorescence. In-vivo experiments in the U-87 MG xenograft model showed that AT101 was able to bind GPC1 on cell surface and accumulate in U-87 MG tumor masses (p = 0.0002 respect to control). Moreover, in-vivo experiments showed that AT101 is able to target GPC1 when conjugated to chitosan NBs, thus increasing their specific deliver to GPC1-expressing cells of U-87 MG tumor, as compared to chitosan NBs not conjugated to AT101 (p = 0.02).

Conclusions: AT101 is an useful targeting agent for the development of drug delivery nanoplatforms for GBM treatment.